CN114392655A - Preparation method of hemodialysis filtration membrane - Google Patents
Preparation method of hemodialysis filtration membrane Download PDFInfo
- Publication number
- CN114392655A CN114392655A CN202111607501.2A CN202111607501A CN114392655A CN 114392655 A CN114392655 A CN 114392655A CN 202111607501 A CN202111607501 A CN 202111607501A CN 114392655 A CN114392655 A CN 114392655A
- Authority
- CN
- China
- Prior art keywords
- spinning
- membrane
- solvent
- purified water
- pvp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012528 membrane Substances 0.000 title claims abstract description 53
- 238000001631 haemodialysis Methods 0.000 title claims abstract description 28
- 230000000322 hemodialysis Effects 0.000 title claims abstract description 28
- 238000001914 filtration Methods 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 50
- 238000009987 spinning Methods 0.000 claims abstract description 46
- 239000008213 purified water Substances 0.000 claims abstract description 22
- 238000000502 dialysis Methods 0.000 claims abstract description 10
- 239000003053 toxin Substances 0.000 claims abstract description 10
- 231100000765 toxin Toxicity 0.000 claims abstract description 10
- 239000000126 substance Substances 0.000 claims abstract description 9
- 230000001112 coagulating effect Effects 0.000 claims abstract description 8
- 238000001035 drying Methods 0.000 claims abstract description 7
- 238000005406 washing Methods 0.000 claims abstract description 6
- 238000001891 gel spinning Methods 0.000 claims abstract description 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 21
- 230000015271 coagulation Effects 0.000 claims description 21
- 238000005345 coagulation Methods 0.000 claims description 21
- 239000002904 solvent Substances 0.000 claims description 21
- 239000007788 liquid Substances 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 10
- 238000001125 extrusion Methods 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- UNZSJASIKFONPS-UHFFFAOYSA-N C(C)(=O)N(C)C.[N].[N] Chemical group C(C)(=O)N(C)C.[N].[N] UNZSJASIKFONPS-UHFFFAOYSA-N 0.000 claims description 3
- 229920012266 Poly(ether sulfone) PES Polymers 0.000 claims description 3
- OXMGUTQVUIWQEK-UHFFFAOYSA-N [N].CC(=O)N(C)C Chemical group [N].CC(=O)N(C)C OXMGUTQVUIWQEK-UHFFFAOYSA-N 0.000 claims description 3
- 229940113088 dimethylacetamide Drugs 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 239000012510 hollow fiber Substances 0.000 claims description 3
- 239000011344 liquid material Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000000523 sample Substances 0.000 claims description 3
- 239000013589 supplement Substances 0.000 claims description 3
- 206010005746 Blood pressure fluctuation Diseases 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 230000036772 blood pressure Effects 0.000 abstract description 6
- 108700012359 toxins Proteins 0.000 description 7
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 208000001953 Hypotension Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000036543 hypotension Effects 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 208000005156 Dehydration Diseases 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 210000003722 extracellular fluid Anatomy 0.000 description 3
- 210000005239 tubule Anatomy 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 206010016807 Fluid retention Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 230000024924 glomerular filtration Effects 0.000 description 2
- 238000007602 hot air drying Methods 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000009103 reabsorption Effects 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002615 hemofiltration Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000885 nephron Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 230000036316 preload Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000010245 tubular reabsorption Effects 0.000 description 1
- 230000010248 tubular secretion Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
- B01D71/06—Organic material
- B01D71/66—Polymers having sulfur in the main chain, with or without nitrogen, oxygen or carbon only
- B01D71/68—Polysulfones; Polyethersulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D67/00—Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
- B01D67/0002—Organic membrane manufacture
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
- B01D69/02—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor characterised by their properties
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
- B01D69/08—Hollow fibre membranes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Manufacturing & Machinery (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- External Artificial Organs (AREA)
Abstract
The invention discloses a preparation method of a hemodialysis filtration membrane, which comprises the following steps: independently preparing two substances, namely spinning solution and core solution; step (2), carrying out dry-wet spinning on the prepared spinning solution and core solution through a spinning nozzle; step (3), dry layer forming; step (4), coagulating in a coagulating bath; step (5), washing with purified water; step (6), drying in an oven; step (7), obtaining a formed dialysis filtration membrane; the invention has the advantages that the hemodialysis filtration can quickly remove a large amount of excessive water; maintaining isotonic water and blood pressure stability; removing the medium-large molecular toxin; the preparation method is simple, the purchase cost can be reduced, and the popularization and the use of enterprises are facilitated.
Description
Technical Field
The invention relates to the technical field of hemodialysis filtration membranes, in particular to a preparation method of a hemodialysis filtration membrane.
Background
Normal human urine production is mainly through glomerular filtration and tubular reabsorption and secretion; hemofiltration is designed by simulating the filtration principle of nephrons, but has no reabsorption function of renal tubules; during the treatment process, a large amount of liquid similar to the extracellular fluid needs to be supplemented to replace the function of the renal tubules;
the hemodialysis filtration is that after the filtration of glomeruli is simulated, a large amount of replacement fluid (fluid with similar extracellular fluid components) is artificially supplemented, the reabsorption function of renal tubules is simulated, and finally, redundant water is filtered to form the water circulation of the kidney;
hemodiafiltration differs from hemodialysis primarily in that it removes solutes by convection, whereas hemodialysis removes solutes by diffusion; the former has the same principle as the normal glomerulus to remove solute, and has the same capacity of removing medium and small molecular substances, while hemodialysis has better removal rate to small molecular substances such as urea and creatinine, and has poorer removal capacity to medium molecular substances; the hemodiafiltration method is that the arterial blood of a patient is introduced into a semipermeable membrane filter which has good permeability and is equivalent to the area of a glomerular filtration membrane, and because a transmembrane pressure gradient exists between a blood area and the outside of the membrane, when the blood passes through the hemodiafiltration device, the blood plasma, except proteins, cells and other visible components, has water and most small molecular substances filtered out, so as to achieve the treatment purpose of removing excessive water and solute remained in the blood; hemodiafiltration is suitable for the following cases 1. refractory hypertension: after the intractable hypertension patients which cannot be controlled by the medicine and the hemodialysis are filtered by the hemodialysis, the blood pressure is recovered to be normal; may be associated with the removal of certain pressurized substances from the plasma during hemodiafiltration; it may also be associated with a more stable cardiovascular system and extracellular fluid during hemodiafiltration, reducing the stimulation of the renin-angiotensin system; 2. water retention and hypotension: for patients with water retention with hypotension, it is not possible to remove enough water by hemodialysis, because hypotension and collapse occur early in dialysis; if the patients change hemodiafiltration, the appearance of circulatory disturbance is obviously improved; the main advantages of hemodiafiltration are the ability to remove large amounts of fluid without causing hypotension; 3. hypervolemic heart failure: the disease condition of the patients is aggravated during hemodialysis, and the heart failure can be relieved or treated by hemodialysis filtration because (i) the hemodialysis filtration can quickly remove excessive water and relieve the heart preload; secondly, although the dehydration effect is good, the blood volume is reduced, but the dehydration belongs to isotonic dehydration, the resistance of peripheral blood vessels is increased, and the stability of the blood pressure is kept; after a large amount of water is removed, the concentration of the plasma albumin is relatively increased, so that the water of surrounding tissues can enter blood vessels, and the edema is reduced; acetate dialysate is not needed, so that vasodilatation and heart contractility inhibition caused by the acetate dialysate are avoided; because of the above advantages, hemodiafiltration is an effective treatment for patients with cardiac insufficiency who are unresponsive to diuretics; hemodiafiltration, while having its advantages, has its disadvantages when used: firstly, because a large amount of replacement liquid needs to be supplemented, the cost is high; volume balance is disordered, if the dialysis filter is not provided with an automatic volume balance device, the dialysis filter is operated manually, and the heart load is increased due to excessive volume or low pressure caused by insufficient volume;
the most important of the existing hemodiafiltration is the preparation of a hemodiafiltration membrane, but the preparation mode of the existing hemodiafiltration membrane is relatively complex and is not good in use.
Disclosure of Invention
Because the existing hemodialysis filtration membrane is complex in preparation mode and poor in use, a preparation method of the hemodialysis filtration membrane is designed on the basis of the defects of the prior art, and the hemodialysis filtration membrane is convenient to prepare and good in use effect.
The technical scheme of the invention is that the preparation method of the hemodialysis filtration membrane comprises the following steps:
independently preparing two substances, namely spinning solution and core solution;
step (2), carrying out dry-wet spinning on the prepared spinning solution and core solution through a spinning nozzle;
step (3), dry layer forming;
step (4), coagulating in a coagulating bath;
step (5), washing with purified water;
step (6), drying in an oven;
and (7) obtaining the formed dialysis filtering membrane.
In addition to the technical scheme, the spinning solution is prepared from the following raw materials in percentage by weight: 70-80% of solvent, 15-25% of membrane material, 78-4% of PVP2 and 0-3% of purified water; wherein the solvent is nitrogen-nitrogen Dimethylacetamide (DMAC), and the membrane material is polyether sulfone (PES); the PVP adopts 80% PVP, K90 or 20% PVP, K30, so that membrane micropores with proper sizes are formed; 80% of PVP and K90 can generate micropores to remove large molecular toxin; 20% PVP, K30, can produce little micropore, clear away water and small molecular toxin, keep micropore aperture size homogeneity, keep certain membrane internal and external differential pressure stable simultaneously, avoid the blood pressure fluctuation in the dialysis process.
Further supplementing the technical scheme, the preparation method of the spinning solution comprises the following steps: (1) mixing and extruding PVP, a membrane material and 25-30% of solvent in screw extrusion, and uniformly mixing to form a primary high-viscosity spinning solution; (2) after extrusion is qualified, putting the mixture into a stirring preparation kettle, and adding 50% of solvent and 0-3% of purified water; (3) heating to 80-85 deg.C to dissolve for 6-8 hr, and defoaming under negative pressure of 0.3-0.5bar for 2-3 hr until the spinning solution is clear and transparent.
In addition to the technical scheme, the core liquid is prepared from the following raw materials in percentage by weight: 40-50% of solvent and 50-60% of purified water, wherein the solvent is nitrogen dimethyl acetamide.
The technical scheme is further supplemented, in the step (2), the spinning is carried out under the condition of 40-50 ℃, the middle core liquid is introduced, the spinning components of the spinning liquid are discharged at the periphery, and the liquid material enters the dry layer after passing through the spinning components to form the semisolid hollow fiber membrane.
In the step (3), a temperature and humidity probe is arranged on the dry layer and fed back to the steam generator, a small amount of clean air with the humidity of 60-80% and the temperature of 45-50 ℃ is injected into the spinning dry layer through a tiny channel, and the air in the dry layer is extracted by micro negative pressure from the other side of the dry layer, wherein the air contains water vapor and DMAC steam.
Supplementing the technical scheme further, in the step (4), the temperature of the high coagulation bath is 55-65 ℃, the concentration of the high coagulation bath is 3-5%, and the most loose outer surface is formed; wherein a circulating water pump is arranged in the coagulation bath, a refractometer is connected to the circulating pipeline, the concentration of DMAC in the concentration of the coagulation bath is detected on line, and the circulating water pump automatically supplements the DMAC according to the concentration; the spinning solution per liter needs to be supplemented with 40-50L of purified water of a coagulation bath, the water amount of the coagulation bath is kept in an overflow mode, purified water and DMAC (dimethylacetamide) are circularly injected, and the stable coagulation bath temperature and the stable DMAC concentration are kept.
The technical proposal is further supplemented, and in the step (5), purified water with the temperature of 60-80 ℃ is adopted for cleaning, and the solvent is removed.
The technical proposal is further supplemented, and the drying of the baking oven in the step (6) adopts 3-8 levels of 100-120 ℃ hot air drying.
The beneficial effects are that the hemodialysis filtration can quickly remove a large amount of excessive water; maintaining isotonic water and blood pressure stability; removing the medium-large molecular toxin; the preparation method is simple, the purchase cost can be reduced, and the popularization and the use of enterprises are facilitated.
Detailed Description
Because the existing hemodialysis filtration membrane is complex in preparation mode and poor in use, a preparation method of the hemodialysis filtration membrane is designed on the basis of the defects of the prior art, and the hemodialysis filtration membrane is convenient to prepare and good in use effect.
In order to make the technical solution more clear to those skilled in the art, the technical solution of the present invention will be explained in detail below:
a preparation method of a hemodialysis filtration membrane comprises the following steps:
independently preparing two substances, namely spinning solution and core solution;
step (2), carrying out dry-wet spinning on the prepared spinning solution and core solution through a spinning nozzle; the spinning is that under the condition of 40-50 ℃, the middle core liquid is introduced, the spinning components of the spinning liquid are discharged at the periphery, and the liquid material enters the dry layer after passing through the spinning components to form the semi-solid hollow fiber membrane.
Step (3), dry layer forming; the dry layer is provided with a temperature and humidity probe which feeds back to a steam generator, a small amount of clean air with the humidity of 60-80% and the temperature of 45-50 ℃ is injected into the spinning dry layer through a tiny channel, and the air in the dry layer is extracted by micro negative pressure at the other side of the dry layer, wherein the air contains water vapor and DMAC steam.
Step (4), coagulating in a coagulating bath; the temperature of the high coagulation bath is 55-65 ℃, the concentration of the high coagulation bath is 3-5%, and the most loose outer surface is formed; wherein a circulating water pump is arranged in the coagulation bath, a refractometer is connected to the circulating pipeline, the concentration of DMAC in the concentration of the coagulation bath is detected on line, and the circulating water pump automatically supplements the DMAC according to the concentration; the spinning solution per liter needs to be supplemented with 40-50L of purified water of a coagulation bath, the water amount of the coagulation bath is kept in an overflow mode, purified water and DMAC (dimethylacetamide) are circularly injected, and the stable coagulation bath temperature and the stable DMAC concentration are kept.
Step (5), washing with purified water; washing with purified water at 60-80 deg.C to remove solvent.
Step (6), drying in an oven; the drying in the oven adopts 3-8 layers of hot air drying at 100 ℃ and 120 ℃.
And (7) obtaining the formed dialysis filtering membrane.
When the spinning solution is used, the pressure of the core liquid, the flow rate of the core liquid and the like are adjusted as required, and the spinning solution form a film after a spinning nozzle, so that the required inner hole diameter and the required thickness of the film are achieved.
The spinning solution is prepared from the following raw materials in percentage by weight: the spinning solution is prepared from the following raw materials in percentage by weight: 70-80% of solvent, 15-25% of membrane material, 78-4% of PVP2 and 0-3% of purified water; wherein the solvent is nitrogen-nitrogen Dimethylacetamide (DMAC), and the membrane material is polyether sulfone (PES); the PVP adopts 80% PVP, K90 or 20% PVP, K30, so that membrane micropores with proper sizes are formed; 80% of PVP and K90 can generate micropores to remove large molecular toxin; 20% of PVP and K30 can generate small micropores, remove water and small molecular toxins, keep the pore size uniformity of the micropores, simultaneously keep the pressure difference between the inside and the outside of a certain membrane stable, and avoid the fluctuation of blood pressure in the dialysis process; the PVP and the K30 are materials recorded in Chinese pharmacopoeia, the PVP and the K90 are materials recorded in American pharmacopoeia, and the material selection is based on the biological safety performance of patients.
The preparation method of the spinning solution comprises the following steps: (1) mixing and extruding PVP, a membrane material and 25-30% of solvent in screw extrusion, and uniformly mixing to form a primary high-viscosity spinning solution; (2) after extrusion is qualified, putting the mixture into a stirring preparation kettle, and adding 50% of solvent and 0-3% of purified water; (3) heating to 80-85 ℃ for dissolution, dissolving for 6-8 hours, defoaming for 2-3 hours under the negative pressure of 0.3-0.5bar until the spinning solution is clear and transparent; can keep the size distribution of membrane pore even, keep the isotonic water, keep blood pressure stability, because PES \ PVP is high molecular weight material, normally dissolve evenly very difficult, need great motor stirring, long-time, high temperature dissolve, screw rod co-extrusion can be with the preliminary three kinds of material misce benes of great cutting force, then dilute to suitable prescription and spinning liquid viscosity in the stirred tank again, prevent to produce inhomogeneous membrane silk.
The core liquid is prepared from the following raw materials in percentage by weight: 40-50% of solvent and 50-60% of purified water, wherein the solvent is nitrogen dimethyl acetamide; the formula of the core liquid expands the inner surface of the membrane pore and removes the medium-large molecular toxin; the pore diameter of the micropores on the inner surface of the hemodialysis filtration membrane is 5-10 nm.
The hemodiafiltration membranes obtained above were subjected to the following toxin-clearing data tests, in which the in vitro performance parameter conditions: the flow QD of the dialyzate is 500mL/min, the flow QF of the filtered solution is 10mL/min, the temperature T is 37 ℃, and the dialyzate simulation solution is adopted for detection; the following data were obtained in table 1:
TABLE 1 toxin removal assay
From the data, the hemodialysis filtration membrane of the invention has convenient use and obvious effect.
The technical solutions described above only represent the preferred technical solutions of the present invention, and some possible modifications to some parts of the technical solutions by those skilled in the art all represent the principles of the present invention, and fall within the protection scope of the present invention.
Claims (9)
1. A preparation method of a hemodialysis filtration membrane is characterized by comprising the following steps:
independently preparing two substances, namely spinning solution and core solution;
step (2), carrying out dry-wet spinning on the prepared spinning solution and core solution through a spinning nozzle;
step (3), dry layer forming;
step (4), coagulating in a coagulating bath;
step (5), washing with purified water;
step (6), drying in an oven;
and (7) obtaining the formed dialysis filtering membrane.
2. The preparation method of the hemodiafiltration membrane according to claim 1, wherein the spinning solution is prepared from the following raw materials by weight percent: 70-80% of solvent, 15-25% of membrane material, 78-4% of PVP2 and 0-3% of purified water; wherein the solvent is nitrogen-nitrogen Dimethylacetamide (DMAC), and the membrane material is polyether sulfone (PES); the PVP adopts 80% PVP, K90 or 20% PVP, K30, so that membrane micropores with proper sizes are formed; 80% of PVP and K90 can generate micropores to remove large molecular toxin; 20% PVP, K30, can produce little micropore, clear away water and small molecular toxin, keep micropore aperture size homogeneity, keep certain membrane internal and external differential pressure stable simultaneously, avoid the blood pressure fluctuation in the dialysis process.
3. The method for preparing a hemodiafiltration membrane according to claim 2, wherein the method for preparing the spinning solution comprises the steps of: (1) mixing and extruding PVP, a membrane material and 25-30% of solvent in screw extrusion, and uniformly mixing to form a primary high-viscosity spinning solution; (2) after extrusion is qualified, putting the mixture into a stirring preparation kettle, and adding 50% of solvent and 0-3% of purified water; (3) heating to 80-85 deg.C to dissolve for 6-8 hr, and defoaming under negative pressure of 0.3-0.5bar for 2-3 hr until the spinning solution is clear and transparent.
4. The preparation method of the hemodiafiltration membrane according to claim 3, wherein the bore fluid is prepared from the following raw materials by weight percent: 40-50% of solvent and 50-60% of purified water, wherein the solvent is nitrogen dimethyl acetamide.
5. The method according to claim 4, wherein the spinning in step (2) is performed by introducing the middle outlet liquid and the surrounding outlet spinning liquid into a spinning module at 40-50 ℃, and the liquid material passes through the spinning module and enters the dry layer to form the semi-solid hollow fiber membrane.
6. The method for preparing a hemodiafiltration membrane according to claim 5, wherein in step (3), a temperature and humidity probe is disposed on the dry layer, fed back to the steam generator, and a small amount of clean air with humidity of 60-80% and temperature of 45-50 ℃ is injected into the spun dry layer through a tiny channel, and air in the dry layer is extracted by a tiny negative pressure on the other side of the dry layer, wherein the air is air containing water vapor and DMAC vapor.
7. The process for preparing a hemodiafiltration membrane according to claim 6, wherein the high coagulation bath temperature of step (4) is 55-65 ℃, the high coagulation bath concentration is 3-5%, forming the most porous outer surface; wherein a circulating water pump is arranged in the coagulation bath, a refractometer is connected to the circulating pipeline, the concentration of DMAC in the concentration of the coagulation bath is detected on line, and the circulating water pump automatically supplements the DMAC according to the concentration; the spinning solution per liter needs to be supplemented with 40-50L of purified water of a coagulation bath, the water amount of the coagulation bath is kept in an overflow mode, purified water and DMAC (dimethylacetamide) are circularly injected, and the stable coagulation bath temperature and the stable DMAC concentration are kept.
8. The process for preparing a hemodiafiltration membrane according to claim 7, wherein in step (5), the solvent is removed by washing with purified water at 60-80 ℃.
9. The method as claimed in claim 8, wherein the step (6) of drying by hot air is performed at a temperature of 120 ℃ and a temperature of 3-8 levels 100 ℃.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111607501.2A CN114392655A (en) | 2021-12-24 | 2021-12-24 | Preparation method of hemodialysis filtration membrane |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111607501.2A CN114392655A (en) | 2021-12-24 | 2021-12-24 | Preparation method of hemodialysis filtration membrane |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114392655A true CN114392655A (en) | 2022-04-26 |
Family
ID=81227630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111607501.2A Pending CN114392655A (en) | 2021-12-24 | 2021-12-24 | Preparation method of hemodialysis filtration membrane |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114392655A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114733369A (en) * | 2022-05-09 | 2022-07-12 | 苏州君康医疗科技有限公司 | Plasma separation membrane and production method of plasma component separation membrane |
Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996035504A1 (en) * | 1995-05-09 | 1996-11-14 | Teijin Limited | Hollow-fiber membrane of polysulfone polymer and process for the production thereof |
| CN1158273A (en) * | 1995-06-30 | 1997-09-03 | 东丽株式会社 | Polysulfone hollow fiber semipermeable membrane |
| KR19980013964A (en) * | 1996-08-06 | 1998-05-15 | 구광시 | A method of manufacturing a blood dialysis membrane excellent in blood bonding property |
| CN1579603A (en) * | 2003-08-13 | 2005-02-16 | 天津膜天膜工程技术有限公司 | Polyether suplphone hollow fiber membrane preparing method |
| JP2005270633A (en) * | 2004-12-06 | 2005-10-06 | Toyobo Co Ltd | Permselective separation membrane |
| JP2006204876A (en) * | 2004-12-27 | 2006-08-10 | Toyobo Co Ltd | Method of manufacturing polysulfone-based hollow fiber membrane |
| JP2006304826A (en) * | 2005-04-26 | 2006-11-09 | Toyobo Co Ltd | Blood purification device |
| US20110017660A1 (en) * | 2008-02-21 | 2011-01-27 | Toyo Boseki Kabushiki Kaisha | Hollow-fiber ultrafiltration membrane with excellent fouling resistance |
| EP2551086A1 (en) * | 2011-07-28 | 2013-01-30 | Gambro Lundia AB | Process for producing a spinning solution |
| CN104190271A (en) * | 2014-08-19 | 2014-12-10 | 苏州君康医疗科技有限公司 | Polyether sulfone/alginate composite hollow fiber membrane and preparation method thereof |
| CN104602798A (en) * | 2013-09-05 | 2015-05-06 | 甘布罗伦迪亚股份公司 | Permselective asymmetric membranes |
| CN110975652A (en) * | 2019-12-10 | 2020-04-10 | 苏州君康医疗科技有限公司 | Infant hemodialysis membrane and preparation method thereof |
| CN112535956A (en) * | 2020-11-17 | 2021-03-23 | 上海翊科聚合物科技有限公司 | Super-hydrophobic polyolefin hollow fiber membrane for oxygen-containing membrane and preparation method thereof |
-
2021
- 2021-12-24 CN CN202111607501.2A patent/CN114392655A/en active Pending
Patent Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996035504A1 (en) * | 1995-05-09 | 1996-11-14 | Teijin Limited | Hollow-fiber membrane of polysulfone polymer and process for the production thereof |
| CN1158273A (en) * | 1995-06-30 | 1997-09-03 | 东丽株式会社 | Polysulfone hollow fiber semipermeable membrane |
| KR19980013964A (en) * | 1996-08-06 | 1998-05-15 | 구광시 | A method of manufacturing a blood dialysis membrane excellent in blood bonding property |
| CN1579603A (en) * | 2003-08-13 | 2005-02-16 | 天津膜天膜工程技术有限公司 | Polyether suplphone hollow fiber membrane preparing method |
| JP2005270633A (en) * | 2004-12-06 | 2005-10-06 | Toyobo Co Ltd | Permselective separation membrane |
| JP2006204876A (en) * | 2004-12-27 | 2006-08-10 | Toyobo Co Ltd | Method of manufacturing polysulfone-based hollow fiber membrane |
| JP2006304826A (en) * | 2005-04-26 | 2006-11-09 | Toyobo Co Ltd | Blood purification device |
| US20110017660A1 (en) * | 2008-02-21 | 2011-01-27 | Toyo Boseki Kabushiki Kaisha | Hollow-fiber ultrafiltration membrane with excellent fouling resistance |
| EP2551086A1 (en) * | 2011-07-28 | 2013-01-30 | Gambro Lundia AB | Process for producing a spinning solution |
| CN104602798A (en) * | 2013-09-05 | 2015-05-06 | 甘布罗伦迪亚股份公司 | Permselective asymmetric membranes |
| CN104190271A (en) * | 2014-08-19 | 2014-12-10 | 苏州君康医疗科技有限公司 | Polyether sulfone/alginate composite hollow fiber membrane and preparation method thereof |
| CN110975652A (en) * | 2019-12-10 | 2020-04-10 | 苏州君康医疗科技有限公司 | Infant hemodialysis membrane and preparation method thereof |
| CN112535956A (en) * | 2020-11-17 | 2021-03-23 | 上海翊科聚合物科技有限公司 | Super-hydrophobic polyolefin hollow fiber membrane for oxygen-containing membrane and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 徐天成等: "聚砜类血液透析膜材料和结构研究进展", 《膜科学与技术》, vol. 38, no. 1, pages 133 - 139 * |
| 金国珍: "《工程塑料》", 31 January 2001, 化学工业出版社, pages: 483 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114733369A (en) * | 2022-05-09 | 2022-07-12 | 苏州君康医疗科技有限公司 | Plasma separation membrane and production method of plasma component separation membrane |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8197745B1 (en) | Perm selective asymmetric hollow fibre membrane for the separation of toxic mediators from blood | |
| JPH06205954A (en) | New high flux hollow fiber membrane | |
| JPH0554373B2 (en) | ||
| CN101703893A (en) | Hollow fiber ultrafiltration composite membrane, preparation method and application thereof | |
| US5851394A (en) | Module for blood purification, blood purification membrane and its production | |
| CN104602798A (en) | Permselective asymmetric membranes | |
| JPH10108907A (en) | Membrane for hemocatharsis, its preparation and module for hemocatharsis | |
| JP2792556B2 (en) | Blood purification module, blood purification membrane and method for producing the same | |
| CN114392655A (en) | Preparation method of hemodialysis filtration membrane | |
| Ronco et al. | Dialysis membranes in convective treatments | |
| JP2009095515A (en) | Blood purifier excellent in volume liquid substitution characteristic | |
| JP4103037B2 (en) | Diaphragm cleaning hollow fiber membrane and method for producing the same | |
| JP2703266B2 (en) | Polysulfone hollow fiber membrane and method for producing the same | |
| JP4055634B2 (en) | Hemodialysis membrane and method for producing the same | |
| JPH0211263B2 (en) | ||
| JP5614470B2 (en) | Blood purifier with excellent mass replacement characteristics | |
| JPH09220455A (en) | Hollow yarn type selective separation membrane | |
| KR20050078748A (en) | A blood compatible hollow fiber membrane, and a process of preparing for the same | |
| JP4381022B2 (en) | Hollow fiber blood purification membrane | |
| CN1173772C (en) | New material and manufacturing method of ascites ultrafiltration concentration return device | |
| JP2005021510A (en) | Highly permeabile hollow fiber type hemocatharsis device | |
| JP2000210544A (en) | Production of semipermeable membrane | |
| JP2002186667A (en) | Hollow fiber type hemodialyzer | |
| JP3413985B2 (en) | Selective separation membrane and blood processing apparatus using the same | |
| CN119368020A (en) | A hemodialysis hollow fiber membrane and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |